Literature DB >> 12657934

Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland.

Robyn L Gaffney1, J Aidan Carney, Thomas J Sebo, Lori A Erickson, Marco Volante, Mauro Papotti, Ricardo V Lloyd.   

Abstract

Galectin-3, a beta-galactoside-binding lectin, is overexpressed in many neoplasms and may be useful when differentiating between benign and malignant thyroid neoplasms. Recently, interest has focused on the classification and biologic behavior of hyalinizing trabecular tumors (HTTs). In this study we compared galectin-3 expression in a number of different thyroid neoplasms to gain insight into the biologic behavior of HTT. Formalin-fixed, paraffin-embedded tissues from 153 thyroid neoplasms were stained with a monoclonal antibody to galectin-3. These tumors included 58 HTTs, 60 papillary carcinomas, 21 follicular carcinomas, and 14 follicular adenomas. Reactivity was graded as negative, weak, or strong by three observers. The average patient age was similar in the patients with HTTs, papillary carcinomas, and follicular adenomas. The patients with follicular carcinomas were approximately a decade older than all other groups of patients. All groups of thyroid neoplasms occurred more frequently in female patients. Follow-up revealed metastatic disease in patients with papillary (36.6%) and follicular carcinomas (19%) but not in patients with follicular adenomas or HTTs. Galectin-3 immunostaining showed that 60% of the HTTs were negative or had weak (H) (1+) staining and 40% had strong (2-3+) staining. In the majority of the reactive cases, staining was diffuse and predominantly cytoplasmic. Fifty of the 60 (83%) papillary carcinomas and 11 of the 21 (52%) follicular carcinomas showed strong immunostaining. The immunostaining was also diffuse in the majority of papillary and follicular carcinomas. The strong immunoreactivity seen in most of the carcinomas was in contrast to the relatively weak or negative immunostaining in the majority of follicular adenomas (93%). The immunophenotype of HTT, as characterized by galectin-3 expression, is intermediate between that of benign and malignant thyroid tumors, suggesting that some tumors with strong staining may behave like carcinomas, although this was not noted in our cases. Our study suggests that the variable pattern of galectin-3 expression may reflect a difference in biologic behavior between HTT and papillary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657934     DOI: 10.1097/00000478-200304000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  Neuroendocrine differentiation in hyalinizing trabecular tumor of the thyroid.

Authors:  Yasuyoshi Shikama; Tadaharu Osawa; Nobuo Yagihashi; Hidekachi Kurotaki; Soroku Yagihashi
Journal:  Virchows Arch       Date:  2003-12       Impact factor: 4.064

Review 2.  Expression of galectins in cancer: a critical review.

Authors:  Frédéric van den Brûle; Stèphane Califice; Vincent Castronovo
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

3.  Human galectin-3 immunoexpression in thyroid follicular adenomas with cell atypia.

Authors:  C Nucera; E Mazzon; B Caillou; M A Violi; M Moleti; C Priolo; G Sturniolo; D Puzzolo; V Cavallari; F Trimarchi; F Vermiglio
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

4.  Hyalinizing trabecular tumor of the thyroid: a case report.

Authors:  P Caraci; A Fulcheri; C Ondolo; F Laino; M Volante; S Aversa
Journal:  Head Neck Pathol       Date:  2011-07-01

5.  [Hyalinizing trabecular tumor of the thyroid. An overcautious designation of a benign thyroid tumour?].

Authors:  S Ting; C Puttinger; K W Schmid; S-Y Sheu-Grabellus
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

6.  Hyalinizing trabecular tumor of the thyroid: an update.

Authors:  Vânia Nosé; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

7.  Galectin-3 Immunohistochemical Expression in Thyroid Neoplasms.

Authors:  B S Sumana; Sampangiram Shashidhar; A S Shivarudrappa
Journal:  J Clin Diagn Res       Date:  2015-11-01

Review 8.  The Diagnosis of Hyalinizing Trabecular Tumor: A Difficult and Controversial Thyroid Entity.

Authors:  Esther Diana Rossi; Mauro Papotti; William Faquin; Luigi Maria Larocca; Liron Pantanowitz
Journal:  Head Neck Pathol       Date:  2019-09-30

Review 9.  Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis.

Authors:  Leandro Luongo de Matos; Adriana Braz Del Giglio; Carolina Ogawa Matsubayashi; Michelle de Lima Farah; Auro Del Giglio; Maria Aparecida da Silva Pinhal
Journal:  Diagn Pathol       Date:  2012-08-13       Impact factor: 2.644

10.  Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Authors:  Duško Dunđerović; Jasmina Marković Lipkovski; Ivan Boričic; Ivan Soldatović; Vesna Božic; Dubravka Cvejić; Svetislav Tatić
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.